BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Inventories, Finished Goods

: $6.2 Mil (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

BioCryst Pharmaceuticals's quarterly finished goods increased from Jun. 2023 ($5.1 Mil) to Sep. 2023 ($6.6 Mil) but then declined from Sep. 2023 ($6.6 Mil) to Dec. 2023 ($6.2 Mil).

BioCryst Pharmaceuticals's annual finished goods increased from Dec. 2021 ($0.7 Mil) to Dec. 2022 ($4.8 Mil) and increased from Dec. 2022 ($4.8 Mil) to Dec. 2023 ($6.2 Mil).

BioCryst Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for BioCryst Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

4.55

0.71

4.81

6.24

BioCryst Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventories, Finished Goods																4.81	4.40	5.08	6.58	6.24

BioCryst Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

BCRX:Mexico BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

http://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Executives

Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse	director, officer: CEO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer	officer: Vice President and CCO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones	officer: Exec Director, Finance - PAO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes	officer: VP, General Counsel & Corp Sec	1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle	officer: Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu	officer: VP Drug Discovery	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie	director	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan	officer: SR VP - CMO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee	director	4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson	director	C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703